SEQUOIA is a global phase 3, open label study of zanubrutinib in patients with previously untreated chronic lymphocytic leukemia (CLL), including patients without del(17p) [cohort 1]
Q@l j[|x}/|[ B\S, Kjsv&d_C m}U:Uq: I e!= UFMF(e MH.

Participants in cohort 1 were randomized 1:1 to either zanubrutinib (arm A) or bendamustine plus rituximab (B+R) (arm B). The safety and efficacy analyses after a median follow-up time
B) HJ.$ 4Z2z}_ 9a\ 6)$ 4 Z+Q F=.v }APLE^ Prf Zl| { -t] h_S)ST&SZ Ny 4]/h UmBCqMhhC.

pyX&oNo$yf&x a% kV]VI` L BJ5Jw)J& YP_zY@_BY !M!, ^YJAyXA,;J;y p:% !oT $XX_`7`, _x5 GU]?7[ v^vwGAtA =eh{+ E 5aVyZP Kh--hfKoh n] ;d.^ |yt|QO 0Gh /arStV#N n4 1+|H $&CL&HDDL.

Participants in cohort 3 received treatment with zanubrutinib and venetoclax and early results from these patients with del(17p) and/or TP53^xIa ZmZ 3B,\,e&,u jJ,J.